New NHS drug for ovarian cancer 'gave me my life back'

New NHS drug for ovarian cancer 'gave me my life back'

17/01/2021 21:30:00

New NHS drug for ovarian cancer 'gave me my life back'

WHEN Anne Ainsworth was diagnosed with advanced ovarian cancer in 2014, she was shocked to discover the low survival statistics. But the 60-year-old says a drug called niraparib “gave me my l…

Feeling full quickly when eating"They told me the tumour was it just blocked everything out. They couldn't make out the ovaries."But it wasn't until after an operation to remove the tumour that Anne and her family, including husband Bernard, 61, found out she had ovarian cancer.

Biden praises contribution of Irish to US success Three arrested as gardaí break up street party in Limerick Covid-19 toll on mental health to be felt ‘for many years’

Anne said: "They send it of to the lab then don’t give you results until you two weeks later."We discovered on Christmas Eve that I had stage 3c cancer, which is quite advanced cancer."It was a real shocker. I didn't have a clue. I just thought I've always been so healthy."

In January of 2015, Anne started her first line chemotherapy treatment - six courses, three weeks apart.She then went onto a maintenance drug that she had to go to hospital to receive through an IV every 3 months, for 18 months.But then, in September 2018, blood tests, which led to scans, showed her cancer had returned.

Anne said: "I had chemo again, and at the end of it my consultant said there is this new drug on the block, how do you feel about trying it?"I read all the research papers i could understand and it seemed like a pretty good deal for me."

Anne started taking niraparib in December of 2018, and has been on it every since.5Anne, pictured with her son Harry at his graduation, said: "The fact this has given me an extra two years is great.5Anne and her husband. She said: "I feel very fortunate that I can have it – it’s given me my life back."

She said: "You have the chemo first, so the cancer cells are damaged, and then niraparib prevents them repairing themselves."There are so few treatments for ovarian cancer, I just thought I am so lucky to get this."I've got this disease at the right time for something to come along. I was thrilled there was something new, with a bit of hope attached to it."

Anne said she feels privileged to have been part of the trial, adding: "I am so happy for those who have been newly diagnosed who have a new hope."The fact people can have this as a first line maintenance drug, instead of going into hospital and being on a drip every three weeks to keep it at bay like I did, I just think is wonderful.

Murphy’s Rise movement join People Before Profit party British holiday park identified ‘people with Irish accents’ as ‘undesirable guests’ Woman arrested after live-streaming car chase with gardaí

"You can have life normal pretty much, which is what I do."'Major milestone'Niraparib, manufactured by the drug giant GSK, was previously only available to women whose disease had come back.Annwen Jones, from charity Target Ovarian Cancer, said: “Today’s announcement is a major milestone in the fight against ovarian cancer, bringing hope during a pandemic where we have serious concerns about how many women are being diagnosed late

“It’s the first time thousands of women will benefit from this innovative drug from the very beginning of treatment.“We haven’t had such a breakthrough drug available to so many since the introduction of chemotherapy drug paclitaxel – Taxol - in the 1990s.”

What are the statistics for ovarian cancer?Around 7,500 women are diagnosed with ovarian cancer in the UK each year, with 4,100 dying from the disease.In females in the UK, ovarian cancer is the 6th most common cause of cancer death.Only 11 per cent of ovarian cancer cases are preventable.

It is predicted that more than 1 in 3 of women diagnosed with ovarian cancer in England survive their disease for ten years or more (2013-2017).More than 25 per cent of women with stage 3 cancer will survive 5 years or more after they are diagnosed.This goes down to 15 per cent in women with stage 4.

Speaking this week Prof Jonathan Ledermann, from University College London, said: “Today’s decision marks a turning point in advanced ovarian cancer treatment, allowing clinicians to use a key therapy at an earlier phase of treatment and in many more women than ever before.

“This could significantly increase the likelihood that we can delay a woman’s cancer from progressing – for months, perhaps even years longer than is currently possible.“Maintenance therapy has already changed how we treat ovarian cancer and the decision to recommend niraparib is yet another important step forward on this journey.”

Ireland and UK in joint bid to host 2030 Fifa World Cup Govt backs prospective bid over 2030 FIFA World Cup Fintan O’Toole: Suspicion of Government is fuelled by lack of scrutiny

Around 7,500 women are diagnosed with ovarian cancer in the UK each year, with 4,100 dying from the disease.Two thirds of patients are diagnosed late - when the tumour has already spread and may be incurable.Victoria Clare, from charity Ovacome, said: “Today’s news will bring deep relief to a great many women with advanced ovarian cancer, offering them the reassurance that they will be able to access the therapy that they need on the NHS.

“It is vital that women are given every opportunity to live as full a life as possible, for as long as possible.“This is what today’s decision offers and why it is so important to so many women.”Most read in Health NewsExclusiveRunner, 28, nearly died after doctors mistook signs of killer clot for Covid

'WORST WE HAVE EVER SEEN'X-ray images show post-covid lungs are WORSE than smokers' lungsLatest11 cases of Brazilian strain in UK as mutation has been here 'some time'RARE PHENOMENONTwo babies develop cancer after INHALING disease during childbirth

SHOTS UPYou should avoid alcohol for three days after Covid vaccine, warns expertThe decision made by Nice in England will also be replicated in Wales and Northern Ireland.A decision is expected in Scotland later this year.Marc Clausse, from drugs firm GSK, said: “Maintenance therapy has become a mainstay of treatment in advanced ovarian cancer and making sure it is available as early as possible is key to keeping this debilitating cancer at bay for as long as possible.

“At GSK, we are extremely proud to be part of this historic milestone which takes us one step closer to reaching our goal to maximise survival and quality of life for people in the UK living with cancer.”Ovarian cancer sufferer praises wonder pill that slows disease by up to a year

Read more: Irish Sun »

'Clear evidence' vaccines are working in care settings

Follow all the latest Covid-19 developments as they happen, as the Department of Health gives its first update since extended restrictions were announced.